Optimizing the dose of dabigatran etexilate

被引：1

作者：

Posner, John ^{[1
]}

机构：

[1] Kings Coll London, Sch Biomed Sci, London WC2R 2LS, England

来源：

BRITISH JOURNAL OF CLINICAL PHARMACOLOGY | 2012年 / 74卷 / 05期

关键词：

THROMBIN INHIBITOR DABIGATRAN; RE-LY TRIAL; ATRIAL-FIBRILLATION; PHARMACODYNAMICS; PHARMACOKINETICS; WARFARIN; TOLERABILITY; THERAPY;

D O I：

10.1111/j.1365-2125.2012.04353.x

中图分类号：

R9 [药学];

学科分类号：

1007 ;

摘要：

引用

页码：741 / 743

页数：3

共 13 条

[1] Perspective on dabigatran etexilate dosing: why not follow standard pharmacological principles? [J].

Chin, Paul K. L. ;

Vella-Brincat, Jane W. A. ;

Barclay, Murray L. ;

Begg, Evan J. .

BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 2012, 74 (05) :734-740

[2]

CHMP post-authorisation summary of opinion for Pradaxa, EMA 337053 2012

[3] Dabigatran versus Warfarin in Patients with Atrial Fibrillation. [J].

Connolly, Stuart J. ;

Ezekowitz, Michael D. ;

Yusuf, Salim ;

Eikelboom, John ;

Oldgren, Jonas ;

Parekh, Amit ;

Pogue, Janice ;

Reilly, Paul A. ;

Themeles, Ellison ;

Varrone, Jeanne ;

Wang, Susan ;

Alings, Marco ;

Xavier, Denis ;

Zhu, Jun ;

Diaz, Rafael ;

Lewis, Basil S. ;

Darius, Harald ;

Diener, Hans-Christoph ;

Joyner, Campbell D. ;

Wallentin, Lars .

NEW ENGLAND JOURNAL OF MEDICINE, 2009, 361 (12) :1139-1151

[4] New Options in Anticoagulation for Atrial Fibrillation [J].

del Zoppo, Gregory J. ;

Eliasziw, Misha .

NEW ENGLAND JOURNAL OF MEDICINE, 2011, 365 (10) :952-953

[5] Risk of Bleeding With 2 Doses of Dabigatran Compared With Warfarin in Older and Younger Patients With Atrial Fibrillation An Analysis of the Randomized Evaluation of Long-Term Anticoagulant Therapy (RE-LY) Trial [J].

Eikelboom, John W. ;

Wallentin, Lars ;

Connolly, Stuart J. ;

Ezekowitz, Mike ;

Healey, Jeff S. ;

Oldgren, Jonas ;

Yang, Sean ;

Alings, Marco ;

Kaatz, Scott ;

Hohnloser, Stefan H. ;

Diener, Hans-Christoph ;

Franzosi, Maria Grazia ;

Huber, Kurt ;

Reilly, Paul ;

Varrone, Jeanne ;

Yusuf, Salim .

CIRCULATION, 2011, 123 (21) :2363-U72

[6] Major Hemorrhage and tolerability of warfarin in the first year of therapy among elderly patients with atrial fibrillation [J].

Hylek, Elaine M. ;

Evans-Molina, Carmella ;

Shea, Carol ;

Henault, Lori E. ;

Regan, Susan .

CIRCULATION, 2007, 115 (21) :2689-2696

[7] Population pharmacokinetic analysis of the oral thrombin inhibitor dabigatran etexilate in patients with non-valvular atrial fibrillation from the RE-LY trial [J].

Liesenfeld, K-H ;

Lehr, T. ;

Dansirikul, C. ;

Reilly, P. A. ;

Connolly, S. J. ;

Ezekowitz, M. D. ;

Yusuf, S. ;

Wallentin, L. ;

Haertter, S. ;

Staab, A. .

JOURNAL OF THROMBOSIS AND HAEMOSTASIS, 2011, 9 (11) :2168-2175

[8]

MHRA, 2011, DRUG SAFETY UPDATE, V5, pA2

[9]

Moia M, 2009, NEW ENGL J MED, V361, P2672

[10] Pharmacokinetics and pharmacodynamics of the direct oral thrombin inhibitor dabigatran in healthy elderly subjects [J].

Stangier, Joachim ;

Staehle, Hildegard ;

Rathgen, Karin ;

Fuhr, Reinhold .

CLINICAL PHARMACOKINETICS, 2008, 47 (01) :47-59

← 1 2 →